Analyst Report: CRL

1. EXECUTIVE SUMMARY

Charles River Laboratories rose 7.83% to $337.52 on Friday 6 November 2026, and the research brief identifies no sourced cause for the move. The company reported a Q3 beat and raised 2026 guidance on 4 November, yet the shares fell 7.27% that day and 4.07% the next, leaving the close at $313.02 on 5 November. Friday's gain recovered part of that decline, though the close remains 6.09% below the $359.41 of 30 October. Analysts raised price targets widely on 4 and 5 November, but those sessions were down days, so the target changes do not explain Friday. A rebound after two sharp declines is our inference only. Volume of 1,063,700 was 0.97x the 50-session average, so the rise came on ordinary turnover.

2. THE CATALYST

No catalyst for Friday is established. GuruFocus reported the surge on 6 November without giving a reason, and a MarketWatch headline from the same day describes a strong trading day for the stock, but the body of that article could not be opened.

The nearest dated event is the Q3 report of Wednesday 4 November. Per the company's 8-K, revenue was $982.7M and non-GAAP EPS was $3.09, up 27.2% year over year. Investing.com cited a $2.97 EPS forecast and a $960.16M revenue estimate; GuruFocus used $958.69M for revenue, so the consensus figure varies by source. Organic revenue grew 4.7%, the second straight quarter of organic growth. Non-GAAP operating margin rose 330 basis points to 23.0%, per the 8-K.

Investing.com reported that the company raised 2026 guidance: organic growth is now above 1.5%, and non-GAAP EPS guidance rose $0.15 at the midpoint to $11.35–11.55. The 8-K attributed the raise mainly to stronger DSA performance and a lower tax rate.

Simply Wall St (via Yahoo Finance) reported that the stock fell on both 4 and 5 November despite the beat and raise. A Zacks headline saying the stock rose conflicts with that account and with the daily closes, and may reflect early trading.

3. COMPANY PROFILE

Charles River Laboratories (Healthcare, Diagnostics & Research; market cap $16.17bn) provides drug discovery, non-clinical development and safety testing services. Its Research Models and Services segment supplies purpose-bred rats and mice and related services to researchers. The sector peer group is Life Sciences Tools & Services, including Thermo Fisher, Danaher, IQVIA, Illumina, Waters and Agilent.

Recent results, per the sources:

• Q3 DSA revenue was $596.3M, down 0.7% as reported because of the European Discovery Services divestiture (BioSpace). Organic DSA growth was 5.9% (GuruFocus).
• Q3 Manufacturing revenue was $178.9M, down 6.2% as reported because of the CDMO sale (BioSpace). Organic growth was 7.4% (GuruFocus).
• DSA book-to-bill was 1.09x, the fourth straight quarter above 1x (Benzinga transcript).
• Q3 free cash flow was $207M, and the $400–420M full-year outlook was unchanged (Benzinga transcript).
• Gross and net leverage fell sequentially to 2.3x (Investing.com).
• GAAP EPS was $6.86 against an estimate of $1.22, with the gap reflecting a tax benefit (GuruFocus).

At Q2 on 5 August the company raised guidance, repurchased $100M of stock at an average of $174, and had completed the May 2026 divestitures of its CDMO and Cell Solutions businesses (8-K).

4. DEEP DIVE ANALYSIS

Do fundamentals justify the move? Friday's rise has no identified fundamental driver, so the fundamentals explain the level of the stock more than the day's move. The Q3 print was strong: a beat on both lines, higher guidance, a 330 basis point margin gain and improving book-to-bill. The 4 and 5 November declines are the unexplained part of the sequence. The stock had reached a 52-week high of $379.63 on 29 October, and the brief does not say whether the post-earnings selling was profit-taking after that run. A Yahoo headline from 4 November says the stock "pulls a bear move as rats and mice retreat", but the article did not load, so it is unverified and may refer to the Research Models segment.

Analyst response. Targets rose broadly after the report.

Mizuho raised its target from $295 to $315, but its date is unconfirmed. CLSA downgraded the stock to hold with a $219 target, also undated in the source. Consensus averages differ by source: $304.83 and $308.17 in two sources, and a FactSet mean of $358.07. At $337.52 the close sits below all of the targets listed above.

Peers. Peers rose over the same period: Thermo Fisher +2.63%, IQVIA +2.62%, Illumina +2.47%, Danaher +1.73%, Agilent +1.73% and Waters +1.00%. The S&P 500 gained 0.31%. CRL's move was larger than any peer's, and no source ties Friday to a sector event. Management's comments on improving biopharma demand are the closest sector link in the sources.

Comparable episodes. After Q2 results on 5 August the stock traded up about 5% immediately (StockStory), and it rose after the 24 September Investor Day (Seeking Alpha). The Q3 beat-and-raise drew the opposite reaction.

Bull case. Organic growth has resumed, margins are expanding, leverage is falling, demand commentary is positive and the broker community has lifted targets. Forward P/E is 26.3.

Bear case. The stock fell on a clean beat-and-raise, which suggests expectations were high after a 66.74% year-to-date gain. Part of the guidance raise came from a lower tax rate. Trailing P/E of 366.9 reflects depressed GAAP earnings history. Friday's rise has no stated driver and can reverse.

5. TECHNICAL SNAPSHOT

The close of $337.52 sits above the 50-day average of $305.60 and the 200-day average of $224.56, and 11.1% below the 52-week high of $379.63 set on 29 October. The low of the last ten sessions is $313.02 on 5 November, which is the nearest support. The nearest resistance is $338.54, the 2 November close, followed by $351.87 from 3 November. Friday's volume of 1,063,700 was lighter than the 1.5 to 1.7 million shares traded on each of the five prior sessions, so the rebound drew less participation than the declines.

6. RISK FACTORS

• The Friday move has no confirmed cause, so the reason for the rebound is unknown and can disappear.
• The stock showed large daily swings in the past week, between -7.27% and +7.83%.
• Part of the guidance raise came from a lower tax rate, which is a weaker quality of upside than operating improvement.
• Reported revenue in DSA and Manufacturing is declining because of divestitures.
• Consensus targets and analyst counts conflict across sources, so the sell-side picture is unclear.
• Upcoming events: the brief found no dated catalyst, and the next earnings date was not available in the facts or sources.

7. ACTIONABLE OUTLOOK

Short term (1-2 weeks). Price action depends on whether the stock holds above $313.02. A close back below that level would erase Friday's gain and retest the post-earnings low. A move through $338.54 and then $351.87 would indicate buyers are absorbing the earlier supply. Volume that stays near average on up days would leave the rebound less convincing.

Medium term (1-3 months). Analyst targets, mostly between $345 and $400, sit above the current price, and the guidance raise provides a higher earnings base. The stock's path depends on whether organic growth and DSA bookings continue, and on management delivering the Q4 outlook it said is embedded in guidance, including a Manufacturing margin approaching 40%.

Long term. The thesis of recovering organic growth, wider margins and lower leverage is intact after the Q3 report, and nothing in the brief changes it. This is analysis only and not personal financial advice.